Abstracts tagged "certolizumab pegol"

Abstract Number: L09 • 2019 ACR/ARP Annual Meeting
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial
Merete Lund Hetland¹, Espen A Haavardsholm ², Anna Rudin ³, Dan Nordström ⁴, Mike Nurmohamed ⁵, Bjorn Gudbjornsson ⁶, Jon Lampa ⁷, Kim Hørslev-Petersen ⁸, Till Uhlig ⁹, Gerdur Grondal ¹⁰, Mikkel Østergaard ¹¹, Marte Heiberg ², Jos Twisk ¹², Kristina Lend ⁷, Simon Krabbe ¹³, Joakim Lindqvist ⁷, Anna-Karin Ekwall ¹⁴, Kathrine Lederballe Grøn ¹⁵, Meliha Kapetanovic ¹⁶, Francesca Faustini ⁷, Riitta Tuompo ¹⁷, Tove Lorenzen ¹⁸, Giovanni Cagnotto ¹⁹, Eva Baecklund ²⁰, Oliver Hendricks ²¹, Daisy Vedder ²², Tuulikki Sokka-isler ²³, Tomas Husmark ²⁴, Maud-Kristine Aga Ljoså ²⁵, Eli Brodin ²⁶, Torkell Ellingsen ²⁷, Annika Söderbergh ²⁸, Milad Rizk ²⁹, Åsa Reckner ³⁰, Line Uhrenholt ³¹, Per Larsson ³², Soeren Just ³³, David Stevens ³⁴, Trine Laurberg ³⁵, Gunnstein Bakland ³⁶, Inge Christoffer Olsen ³⁷, Ronald van Vollenhoven ³⁸ and The NORD-STAR Study Group ³⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Diakonhjemmet Hospital, Oslo, Norway, ³Dept Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden, ⁴Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁵Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Department of Rheumatology, King Christian X's Hospital for Rheumatic Diseases Graasten, Denmark, Graasten, Denmark, ⁹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹⁰Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ¹¹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ¹²Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, Netherlands, ¹³Rigshospitalet, København, Denmark, ¹⁴University of Gothenburg, Kullavik, Sweden, ¹⁵Rigshospitalt Glostrup, Glostrup, Denmark, ¹⁶Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹⁷Helsinki University Hospital, Helsinki, Finland, ¹⁸Reumatologi, Regionshospitalet Silkeborg, Kolding, Denmark, ¹⁹Lund University, Malmö, Sweden, ²⁰Uppsala University, Uppsala, Sweden, ²¹Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²²Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, ²³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²⁴Rheumatology Clinic, Falun, Sweden, ²⁵Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ²⁸Örebro University Hospital, Ôrebro, Sweden, ²⁹Västmanlands Hospital, Västerås, Sweden, ³⁰Rheumatology Department, Linkoping, Sweden, ³¹Aalborg Universitetshospital, Aalborg, Denmark, ³²Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³³Odense University Hospital, Odense, ³⁴St. Olav's University Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway, ³⁸Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, ³⁹Site investigators in all participating countries, Stockholm, Sweden
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…
Abstract Number: 1506 • 2019 ACR/ARP Annual Meeting
Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results
Xenofon Baraliakos¹, Sebastian Kruse ², Simone Auteri ³, Natasha de Peyrecave ⁴, Tommi Nurminen ⁵, Thomas Kumke ⁵, Bengt Hoepken ⁶ and Jürgen Braun ², ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Monheim am Rhein, Germany
Background/Purpose: Inflammation of the spine is believed to trigger a repair mechanism that results in syndesmophyte formation in axial spondyloarthritis (axSpA) patients (pts).1 Bone marrow…
Abstract Number: 1507 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Atul Deodhar¹, Lianne Gensler ², Jonathan Kay ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Robert B.M. Landewé ⁶, Martin Rudwaleit ⁷, Stephen Hall ⁸, Lars Bauer ⁹, Bengt Hoepken ⁹, Natasha de Peyrecave ¹⁰, Thomas Kumke ¹¹ and Désirée van der Heijde ¹², ¹Oregon Health & Science University, Portland, OR, ²University San Francisco California, San Francisco, CA, ³UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁸Monash University and Emeritus Research, Melbourne, Australia, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹UCB Pharma, Monheim, Germany, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to…
Abstract Number: 1535 • 2019 ACR/ARP Annual Meeting
Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Laura Coates¹, Joseph Merola ², Arthur Kavanaugh ³, Philip Mease ⁴, Owen Davies ⁵, Oscar Irvin-Sellers ⁶, Tommi Nurminen ⁷ and Désirée van der Heijde ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³University of California, San Diego School of Medicine, La Jolla, CA, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁵UCB Pharma, Slough, England, United Kingdom, ⁶UCB Pharma, Slough, UK, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Several disease activity measures and thresholds have been recommended as psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate assessment tool is…
Abstract Number: 2068 • 2019 ACR/ARP Annual Meeting
Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
Vivian Bykerk¹, Andrew Blauvelt ², Jeffrey Curtis ³, Cécile Gaujoux-Viala ⁴, Tore K. Kvien ⁵, William J. Sandborn ⁶, Kevin Winthrop ⁷, Christina Popova ⁸ and Xavier Mariette ⁹, ¹Hospital for Special Surgery, New York City, NY, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Nîmes University Hospital, Nîmes, France, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of California, La Jolla, CA, ⁷Oregon Health and Science University, Portland, OR, ⁸UCB Pharma, Brussels, Belgium, ⁹Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Certolizumab pegol (CZP) is an anti-TNF drug approved for rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).…
Abstract Number: 587 • 2018 ACR/ARHP Annual Meeting
The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
Ruediger Mueller¹, Michael Spaeth², Cord von Restorff³, Christoph Ackermann⁴ and Johannes von Kempis⁵, ¹Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Spital Linth, Uznach, Switzerland, ³Private rheumatologic practice, Männedorf, Switzerland, ⁴Private rheumatologic practice, Triesen, Liechtenstein, ⁵Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland
The superiority of a treat to target strategy over conventional treatment with fixed csDMARD and corticosteroids: a multi-centre randomized controlled trial in RA patients with…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 622 • 2018 ACR/ARHP Annual Meeting
DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study
Janet E. Pope¹, Emmanouil Rampakakis², Julie Vaillancourt², Eric Grant³, Louis Bessette⁴, Juris Lazovskis⁵, Boulos Haraoui⁶ and John S. Sampalis⁷, ¹Department of Medicine, University of Western Ontario, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Private Practice, Saint John, NB, Canada, ⁴Laval University, Québec, QC, Canada, ⁵Riverside Professional Centre, Sydney, NS, Canada, ⁶Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ⁷McGill University, Montreal, QC, Canada
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) in the treatment of adult patients with moderate to severe rheumatoid arthritis (RA), when administered either…
Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Atul A. Deodhar¹, Lianne S. Gensler², Jonathan Kay³, Walter P. Maksymowych⁴, Nigil Haroon⁵, Robert B.M. Landewé⁶, Martin Rudwaleit⁷, Stephen Hall⁸, Lars Bauer⁹, Bengt Hoepken⁹, Natasha de Peyrecave¹⁰, Brian Kilgallen¹¹ and Désirée van der Heijde¹², ¹Oregon Health and Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, ⁸Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Marianna Meroni¹, Maria De Santis², Elena Generali², Angela Ceribelli³, Marta Caprioli³, Giacomo Maria Guidelli², Natasa Isailovic², Gaetano Maria Fara⁴, Carlo Selmi² and Maurizio Cutolo⁵, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy
Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…
Abstract Number: 2516 • 2018 ACR/ARHP Annual Meeting
Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
Alain Saraux¹, René-Marc Flipo², Francis Fagnani³, Gabrielle Cukierman⁴, Isabelle Bru⁴, Jean-Michel Joubert⁴, Jan-Christof Schuller⁵, Jacques Massol⁶ and Bernard Combe⁷, ¹CHU La Cavale Blanche, Brest, France, ²Hôpital Roger Salengro, Lille, France, ³Cemka-Eval, Bourg-la-Reine, France, ⁴UCB Pharma, Colombes, France, ⁵UCB Pharma, Brussels, Belgium, ⁶CHU de Besançon, Besançon, France, ⁷CHU Lapeyronie, Montpellier, France
Background/Purpose: The safety and efficacy of certolizumab pegol (CZP) for treating patients (pts) with rheumatoid arthritis (RA) are well-established in a clinical trial setting.1,2 However,…
Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Johanna Gehin¹, Silje Watterdal Syversen², Guro Løvik Goll², David J Warren¹, Joseph Sexton³, Eldri Kvein Strand⁴, Tore Kvien^3,5,6, Elisabeth Lie^2,6 and Nils Bolstad⁷, ¹Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Lillehammer Revmatismesykehus, Lillehammer, Norway, ⁵NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁶On behalf of the NOR-DMARD registry, Oslo, Norway, ⁷Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway
Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…
Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Rosa Expósito¹, Carlos M Gonzalez², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷ and Manuel Fernández⁸, ¹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain
Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…
Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data
Arantxa Conesa¹, Manuel Fernández², Rosa Expósito³, Jose Campos⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, Paula Rubio-Muñoz⁷, Pilar Ahijado-Guzman⁸ and Carlos M Gonzalez⁹, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Hospital Universitario de Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ⁴Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ⁹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
Abstract Number: 1519 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study
Carlos M Gonzalez¹, Rosa Expósito², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷, Manuel Fernández⁸ and Mercedes Morcillo⁹, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain, ⁹Rheumatology, Hospital El Escorial, San Lorenzo de el Escorial, Spain
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. RAPID-axSpA trial investigated the efficacy and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].